BIO promotes regulatory and market uptake of biotech for animals

While gene editing holds great promise for helping animals withstand disease, regulatory burdens and barriers to commercialization keep us from realizing its full potential, experts for the Biotechnology Innovation Organization (BIO) told the Animal Agtech Innovation Summit in Dallas, April 8-9.

“Improving disease resilience with conventional breeding methods is very challenging,” according to Mark Walton, BIO Senior Director, Regulatory Affairs. “That’s why gene editing is such an important tool, and we need to be able to…